Drug profile · INN
serplulimab
HETRONIFLY
serplulimab (HETRONIFLY) is a programmed cell death protein 1 antagonist.
EMA: approved NMPA: clinical trials Antineoplastic and immunomodulating agents (L01) L01FF12
Patents linked 1
Pipeline programs 8
News articles 1
Drug details — serplulimab
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 1
- Programs
- 8
- Data quality
- 0.83
Quick answer
serplulimab (HETRONIFLY) is a programmed cell death protein 1 antagonist.
Key facts
INN serplulimab
Brand HETRONIFLY
Mechanism Programmed cell death protein 1 antagonist
Target Programmed cell death protein 1
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01FF12
Mechanism of action
Programmed cell death protein 1 antagonist
Primary target: Programmed cell death protein 1
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| NMPA | clinical trials | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is serplulimab?
serplulimab (HETRONIFLY) is a programmed cell death protein 1 antagonist.
What is the brand name for serplulimab?
HETRONIFLY is a marketed brand name for serplulimab. Check FDA Drugs@FDA for the current US label holder and prescribing information.